Combination expands Asurion's global reach and capabilities across technology and appliance care

NASHVILLE, Tenn., Oct. 8, 2026 /PRNewswire/ -- Asurion, a global leader in technology care, support, and protection, today announced it has completed its acquisition of Domestic & General (D&G), a leading provider of appliance protection across the UK, Europe and beyond. 

By combining Asurion's technology care capabilities with D&G's appliance expertise, strong partner relationships and international reach, the acquisition advances Asurion's strategy to help customers manage and get more from the growing number of connected devices and appliances in their homes. The combination also expands Asurion's presence internationally and in the U.S. appliance market, strengthening its position in the fast-growing, $150+ billion connected home devices market. 

"Technology is becoming more essential to everyday life and more connected and complex," said Guru Gowrappan, Chief Executive Officer of Asurion. "Our job at Asurion is simple: make technology work. Bringing Asurion and Domestic & General together expands our ability to do that across more of the technology and appliances people rely on every day, while extending our reach to millions more customers around the world." 

Domestic & General is a trusted leader in appliance care and protection, with more than a century of experience and partnerships with more than 100 leading brands, including Whirlpool, Sky, Hoover-Candy, and John Lewis.

"Domestic & General has built its business on trusted care, strong partner relationships and deep expertise in appliance care and protection," said Matthew Crummack, Chief Executive Officer of Domestic & General. "Those strengths, combined with Asurion's technology care capabilities and our shared commitment to customer and partner excellence, make this a compelling fit. We're excited about what we can build together in this next chapter of growth." 

There are no immediate changes to how Asurion or D&G serve their customers or partners as a result of the acquisition. Domestic & General will continue to operate under its existing brand within Asurion.

"We're excited to welcome the D&G team to Asurion," Gowrappan continued. "As homes become more connected, customers shouldn't have to navigate a different solution for every device or appliance they own. Together, Asurion and D&G have an opportunity to make that complexity simpler, helping customers protect, manage and get more value from their technology throughout its life." 

Financial terms of the transaction were not disclosed. 

Advisors

Goldman Sachs & Co. LLC acted as lead financial advisor to Asurion. Morgan Stanley & Co. LLC also acted as a financial advisor to Asurion. Hogan Lovells Cadwalader served as Asurion's legal counsel. Rothschild & Co acted as financial advisor to CVC and Latham & Watkins served as CVC's legal counsel. 

About Asurion

Asurion is the leading global tech care company providing protection, repair, replacement, and 24/7 support for all the technology in consumers' lives. With thousands of experts ready to help whenever and wherever, Asurion proudly cares for millions of customers with thousands of different devices. Asurion provides world-class customer experiences that keep tech running, with seamless, intelligent care for nearly every connected device in the home, from phones to major appliances and everything in between. Asurion is ready to help however you need it — online, over the phone, in your neighborhood, or even at your doorstep. We are a partner to the largest enterprise brands, serving over 100 clients. For more information, visit asurion.com. 

About Domestic & General

Domestic & General are the trusted appliance care experts, dedicated to protecting, repairing, and replacing millions of household appliances worldwide. With over 100 years of experience, they partner with leading manufacturers and retailers to provide exceptional customer service and reliable repair solutions. 

Operating in 12 markets, across the UK, Europe, and the US, they protect over 22 million appliances and serve over 7 million subscription customers. Their team of over 4,000 employees are committed to ensuring your home runs smoothly. 

Domestic & General's product range is simple and transparent, designed to protect customers from the cost and inconvenience of appliance breakdowns. Whether it's washing machines, heating systems, TVs, or consumer electronics, they repair over 2.6 million appliances each year. Committed to a sustainable future, they help make repair the first choice for people, businesses, and the planet. 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/asurion-completes-acquisition-of-domestic--general-to-expand-technology-care-across-the-connected-home-302902486.html

Roche versucht nach einer Phase von Forschungsrückschlägen und Belastungen durch auslaufende Patente, das Tempo in der Medikamentenentwicklung deutlich zu erhöhen. Am Pharma-Investorentag unterstrich die Pharmasparte des Basler Konzerns den Anspruch, in Forschung und Entwicklung weiter zur Spitzengruppe zu gehören. Zentral sind dabei ein strengeres Management der Pipeline, Effizienzprogramme und der verstärkte Einsatz künstlicher Intelligenz entlang der Wertschöpfungskette.

Pharma-Chefin Teresa Graham verwies auf eine sichtbar verbesserte Bilanz seit dem letzten „Pharma Day“: In zehn zulassungsrelevanten Studien habe Roche die gesetzten Ziele erreicht, sechs Programme seien in die zulassungsrelevende Phase vorgerückt, drei weitere in Phase II. Insgesamt verfügt Roche nach eigenen Angaben über bis zu 20 neue Wirkstoffe, die bis 2030 auf den Markt kommen könnten. Einzelne Kandidaten wie das Brustkrebsmittel Giredestrant traut der Konzern dabei jeweils Spitzenumsätze im zweistelligen Milliardenbereich zu.

Um diese Ambitionen abzusichern, verschärft Roche die internen Selektionskriterien. Ende 2023 führte der Konzern mit „The Bar“ einen neuen Bewertungsrahmen für die Pipeline ein. Nur Wirkstoffkandidaten, die klar definierte Anforderungen erfüllen, werden weiterentwickelt. Medizinchef Levi Garraway bezeichnete „The Bar“ als Leitbild für Forschung und Entwicklung. Die Auswahl potenzieller Projekte sei damit spürbar strenger geworden – mit dem Ziel, Ressourcen konsequent auf die Erfolg versprechendsten Programme zu konzentrieren und die Erfolgsquote in späten Studienphasen zu stabilisieren oder weiter zu erhöhen.

Parallel dazu treibt Roche ein Effizienzprogramm voran, um Mittel aus weniger renditestarken in wachstumsstärkere Projekte umzuschichten. Die Entwicklung neuer Medikamente soll deutlich beschleunigt werden, was insbesondere in umkämpften Indikationen wie Onkologie sowie in wachstumsstarken Bereichen wie Herz-Kreislauf- und Stoffwechselerkrankungen an Bedeutung gewinnt. Damit will Roche erwartete Umsatzeinbussen durch Patentabläufe mehr als kompensieren und sich bis zum Ende des Jahrzehnts ein Portfolio aufbauen, das von mehreren potenziellen Blockbustern getragen wird.